Does digital health improve equity for Latine mental health after a disaster? Evidence from a randomized trial with 2017 and 2018 hurricane survivors.

Psychol TraumaAug 7, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Arthur R Andrews, Laura M Acosta, Laura Perez Villagomez et al.

✦ AI-curated · Sources linked

In 30 seconds

This analysis of a randomized clinical trial examined whether use and outcomes of Bounce Back Now, a mobile self-help app, differed between Latine and non-Latine hurricane survivors from the 2017 and 2018 seasons. The sample included 1,357 survivors, 49.5% of whom were Latine. App use across components and efficacy were not significantly different between groups (p > .05). About half of participants in both groups who had significant symptoms had not received mental health care in the previous month, suggesting the app reached people with unmet care needs.

Key findings

  • Use of multiple Bounce Back Now components did not differ significantly between Latine and non-Latine participants (p > .05).
  • Efficacy was similar between groups in latent change score models (p > .05).
  • Approximately half of Latine and non-Latine participants with significant symptoms had received no mental health care in the past month.

Why it matters

Digital self-help tools are often proposed to address disparities in mental health access. These findings suggest that this app was used and had similar efficacy across Latine and non-Latine survivors, while reaching many participants with significant symptoms who were not receiving recent care. The results inform efforts to assess whether digital tools can contribute to more equitable access after disasters.

What to keep in mind

The findings concern one mobile self-help app in hurricane survivors and do not establish that digital tools generally reduce mental health disparities.

Source

Published in Psychol Trauma. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.